Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;14(7):735-44.
doi: 10.2217/pgs.13.64.

Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records

Matthew T Oetjens  1 , Joshua C Denny, Marylyn D Ritchie, Niloufar B Gillani, Danielle M Richardson, Nicole A Restrepo, Jill M Pulley, Holli H Dilks, Melissa A Basford, Erica Bowton, Dan R Masys, Russell A Wilke, Dan M Roden, Dana C Crawford
Affiliations

Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records

Matthew T Oetjens et al. Pharmacogenomics. 2013 May.

Abstract

Background: The ADME Core Panel assays 184 variants across 34 pharmacogenes, many of which are difficult to accurately genotype with standard multiplexing methods.

Methods: We genotyped 326 frequently medicated individuals of European descent in Vanderbilt's biorepository linked to de-identified electronic medical records, BioVU, on the ADME Core Panel to assess quality and performance of the assay. We compared quality control metrics and determined the extent of direct and indirect marker overlap between the ADME Core Panel and the Illumina Omni1-Quad.

Results: We found the quality of the ADME Core Panel data to be high, with exceptions in select copy number variants and markers in certain genes (notably CYP2D6). Most of the common variants on the ADME panel are genotyped by the Omni1, but absent rare variants and copy number variants could not be accurately tagged by single markers.

Conclusion: Our frequently medicated study population did not convincingly differ in allele frequency from reference populations, suggesting that heterogeneous clinical samples (with respect to medications) have similar allele frequency distributions in pharmacogenetics genes compared with reference populations.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Prescribed medications among the heavily medicated clinical population
On the x-axis are the 12 classes of medications selected for our heavily medicated cohort definition. The y-axis is the proportion of our clinical population prescribed at least one medication of the given drug class.
See this image and copyright information in PMC

References

    1. Crawford DC, Ritchie MD, Rieder MJ. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics. 2007;8(5):487–496. - PMC - PubMed
    1. Wells QS, Delaney JT, Roden DM. Genetic determinants of response to cardiovascular drugs. Curr.Opin.Cardiol. 2012;27(3):253–261. - PMC - PubMed
    1. Pulley JM, Denny JC, Peterson JF, et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clin.Pharmacol.Ther. 2012;92(1):87–95. - PMC - PubMed

    1. Peters EJ, McLeod HL. Ability of whole-genome SNP arrays to capture ’must have’ pharmacogenomic variants. Pharmacogenomics. 2008;9(11):1573–1577.** Discusses the Pharmacogenetics Research Network’s very important pharmacogenes list and their coverage of genome-wide platforms

    1. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol.Sci. 2011;32(2):72–81. - PubMed

Publication types